Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 17 member A (CLEC17A), also known as prolectin, is a type II transmembrane C-type lectin receptor that is mainly expressed on lymph node B cells. It binds fucosylated glycan motifs present on epithelial cells, facilitating cell adhesion—a property leveraged by some tumor cells to colonize lymph nodes during metastasis. CLEC17A possesses a C-type lectin carbohydrate recognition domain with high specificity for mannose and fucose residues, as well as cytoplasmic motifs implicated in intracellular signaling. Sequence and biochemical analyses suggest a possible role in immune regulation beyond cell adhesion, though its full physiological and pathological significance is still under active investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin domain family 17 member A (CLEC17A).